Last news
Baghdadi Capital Group Selects nCino to Power Global Growth and Expansion Strategy

Baghdadi Capital Group Selects nCino to Power Global Growth and Expansion Strategy

Notified -...

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Notified -...

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Notified -...

Valeura Energy Inc.: Q3 2025 Operations and Financial Update

Valeura Energy Inc.: Q3 2025 Operations and Financial Update

Notified -...

FloQast chosen by Halfords to streamline compliance and prepare for Provision 29

FloQast chosen by Halfords to streamline compliance and prepare for Provision 29

Notified -...

Bar Leone Crowned The World’s Best Bar 2025 in Its Hometown of Hong Kong

Bar Leone Crowned The World’s Best Bar 2025 in Its Hometown of Hong Kong

Notified -...

eXp Realty Launches UK Commercial Division, Expanding Agent Model Into $10B Market

eXp Realty Launches UK Commercial Division, Expanding Agent Model Into $10B Market

Notified -...

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Notified -...

1 2 3 4 5 6 7 8 9 10 ... 920
menu
menu